PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment
Phospholipase A2 (PLA2) designates a large and diverse
group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
A flexible and efficient DC power converter for sustainable-energy microgrids
A new DC-DC power converter is superior to previous designs and paves the way for more efficient, reliable and sustainable energy storage and conversion solutions. The Kobe University development can…
Technical Trials for Easing the (Cosmological) Tension
A new study sorts through models attempting to solve one of the major challenges of contemporary cosmic science, the measurement of its expansion. Thanks to the dizzying growth of cosmic…
